---
title: A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual
  dysphoric disorder.
authors: "['Torbj\xF6rnB\xE4ckstr\xF6m', 'KarinEkberg', 'Angelica Lind\xE9nHirschberg',\
  \ 'MarieBixo', 'C NeillEpperson', 'PaulaBriggs', 'NickPanay', \"ShaughnO'Brien\"\
  ]"
journal: Psychoneuroendocrinology
publication_date: ''
doi: 10.1016/j.psyneuen.2021.105426
pmid: ''
document_type: research_paper
source: PubMed
search_category: pmdd_neurochemistry
search_query: GABA PMDD
tags:
- pmdd
- dopamine
- clinical_research
- serotonin
- premenstrual_dysphoric_disorder
- gaba
- neurotransmitters
- hormones_endocrine
created_date: '2025-10-21'
content_type: research_paper
condition: pmdd
topic: premenstrual_dysphoric_disorder
---

# A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.

## Authors
['TorbjörnBäckström', 'KarinEkberg', 'Angelica LindénHirschberg', 'MarieBixo', 'C NeillEpperson', 'PaulaBriggs', 'NickPanay', "ShaughnO'Brien"]

## Journal
Psychoneuroendocrinology

## Publication Information
- **Year**: 
- **DOI**: 10.1016/j.psyneuen.2021.105426
- **PMID**: 

## Abstract
Women with premenstrual dysphoric disorder (PMDD) experience mood symptoms related to the increase in progesterone and the neuroactive steroid allopregnanolone. Our hypothesis is that allopregnanolone is the symptom provoking factor. The rationale for the present study was to treat PMDD patients with the GABA

## Keywords
pmdd, dopamine, clinical_research, serotonin, premenstrual_dysphoric_disorder, gaba, neurotransmitters, hormones_endocrine

## Source Information
- **Source**: PubMed
- **Search Category**: pmdd_neurochemistry
- **Search Query**: GABA PMDD

---
*This document was automatically processed from PubMed and added to the PMDD research knowledge base.*
